Project Grant F32CA298648
Award Date 1/12/26
Completion Date 7/31/28
Dollars Obligated $151K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- This federal Project Grant award for $226,608.00 was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) grant program. The award supports research conducted by St. Jude Children's Research Hospital Inc. to investigate the mechanism by which a specific gene regulates chromatin function and its implications for the viability of rhabdoid tumors. The research aims to elucidate how the loss of this gene further disrupts the balance between the SWI/SNF chromatin...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $290,017.00 to St. Jude Children's Research Hospital Inc. to investigate the cell state hierarchy and transcriptional/epigenetic determinants of therapy-resistant progenitor-like cells in fusion-negative rhabdomyosarcoma (FN-RMS), a type of pediatric soft tissue sarcoma. The award will support computational and experimental research approaches, including single-cell RNA sequencing,...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Emory University provides $489,527 over a 5-year period starting January 1, 2025. The project aims to enhance the understanding of genetic variants in the SMARCB1 gene and their functional consequences in cancers characterized by SMARCB1 deficiency, which affect children, adolescents, and young adults. The research will focus on assessing how SMARCB1 missense mutations...
- This federal Project Grant award of $667,480.00 was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to St. Jude Children's Research Hospital Inc. The award supports fundamental scientific research and advanced training focused on understanding the regulation of genome expression by chromatin and how mutations in chromatin proteins contribute to oncogenesis. The research aims to provide new insights...
- This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $167,584.00 to the University of California, San Diego (UCSD) to generate human induced pluripotent stem cell (hiPSC) models of atypical teratoid rhabdoid tumors (ATRTs) - an aggressive form of pediatric brain cancer. The primary goals are to investigate the cell of origin for ATRTs and identify potential therapeutic vulnerabilities. Specifically, the award supports research to derive...
- The U.S. National Institute of General Medical Sciences (NIGMS) awarded a $508,750 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to St. Jude Children's Research Hospital Inc. The grant, awarded on August 1, 2025, supports research to elucidate the chromatin structure and function of double minute chromosomes (DMs) throughout the cell cycle. The project aims to develop novel biochemical and chemical strategies to investigate DM chromatin structure,...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to St. Jude Children's Research Hospital Inc. provides $718,113 to fund research on "Targetable Epigenetic Modifiers that Promote Neuroblastoma Malignancy and Plasticity". The project aims to investigate how epigenetic factors, including histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), connect the MYC oncogenes to neuroblastoma-specific...
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 - Cancer Treatment Research to St. Jude Children's Research Hospital Inc. for $768,713 on August 1, 2025. The funding supports research to dissect how the EP300 and CBP histone acetyltransferase proteins control cell state-specific phenotypes and chemosensitivity in high-risk neuroblastoma. The objectives are to capitalize on transcriptional control to identify mechanism-based, targeted cancer therapies that can...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to develop high-quality chemical probes to functionally annotate the epigenetic effector "reader" domains within the Bromodomain PHD Finger Transcription Factor (BPTF) in neuroblastoma, an aggressive pediatric cancer. The $738,024 award, effective from January 1, 2025 to December 31, 2029, aims to optimize BPTF bromodomain and plant homeodomain (PHD)...